NASDAQ:SCNI - Nasdaq - US09073Q3039 - ADR - Currency: USD
NASDAQ:SCNI (2/21/2025, 8:00:01 PM)
3.52
+0.14 (+4.28%)
The current stock price of SCNI is 3.52 USD. In the past month the price decreased by -0.62%. In the past year, price decreased by -28.16%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Scinai Immunotherapeutics Ltd is a IL-based company operating in Biotechnology industry. Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
SCINAI IMMUNOTHERAPEUTICS LT
Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus
JERUSALEM IL
Employees: 31
Company Website: https://www.scinai.com/
Investor Relations: http://www.biondvax.com/investors/
Phone: 97289302529
The current stock price of SCNI is 3.52 USD. The price increased by 4.28% in the last trading session.
The exchange symbol of SCINAI IMMUNOTHERAPEUTICS LT is SCNI and it is listed on the Nasdaq exchange.
SCNI stock is listed on the Nasdaq exchange.
7 analysts have analysed SCNI and the average price target is 714 USD. This implies a price increase of 20184.09% is expected in the next year compared to the current price of 3.52. Check the SCINAI IMMUNOTHERAPEUTICS LT stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a market capitalization of 3.00M USD. This makes SCNI a Nano Cap stock.
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) currently has 31 employees.
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a support level at 3.51 and a resistance level at 3.79. Check the full technical report for a detailed analysis of SCNI support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SCNI does not pay a dividend.
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.7).
The outstanding short interest for SCINAI IMMUNOTHERAPEUTICS LT (SCNI) is 0.05% of its float. Check the ownership tab for more information on the SCNI short interest.
ChartMill assigns a technical rating of 2 / 10 to SCNI. When comparing the yearly performance of all stocks, SCNI is a bad performer in the overall market: 80.91% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to SCNI. SCNI has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SCNI reported a non-GAAP Earnings per Share(EPS) of -18.7. The EPS increased by 108.9% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 561.28% | ||
ROA | 20.69% | ||
ROE | 25.36% | ||
Debt/Equity | 0.03 |
ChartMill assigns a Buy % Consensus number of 83% to SCNI. The Buy consensus is the average rating of analysts ratings from 7 analysts.